Results 281 to 290 of about 245,314 (316)

Treatment of acute ischemic stroke

Journal of Stroke and Cerebrovascular Diseases, 2001
Acute ischemic stroke remains difficult to treat despite the advent of new therapies. The only approved medication to reverse its effects is recombinant tissue plasminogen activator administered intravenously within 3 hours of onset of stroke symptoms--an opportunity that does not often present itself. The principal drawback to thrombolytic therapy for
openaire   +2 more sources

Treatment of acute ischemic stroke

Drugs of Today, 1998
Acute ischemic stroke now is being treated as a medical emergency. The success of the use of tissue plasminogen activator (t-PA) within 3 hours of onset of stroke serves as an impetus for an approach that emphasizes prompt recognition, rapid transportation to a medical center, speedy evaluation and urgent treatment.
H P, Adams, E C, Leira
openaire   +2 more sources

Cyclosporine in acute ischemic stroke

Neurology, 2015
We examined whether IV administration of cyclosporine in combination with thrombolysis might reduce cerebral infarct size.Patients aged 18 to 85 years, presenting with an anterior-circulation stroke and eligible for thrombolytic therapy, were enrolled in this multicenter, single-blinded, controlled trial.
Nighoghossian, N., Berthezene, Y., Mechtouff, L., Derex, L., Cho, T. H., Ritzenthaler, T., Rheims, S., Chauveau, F., Bejot, Y., Jacquin, A., Giroud, M., Ricolfi, F., Philippeau, F., Lamy, C., Turc, G., Bodiguel, E., Domigo, V., Guiraud, V., Mas, J. L., Oppenheim, C., Amarenco, P., Cakmak, S., Sevin-Allouet, M., Guillon, B., Desal, Hubert, Hosseini, H., Sibon, I., Mahagne, M. H., Ong, E., Mewton, Nathan, Ovize, Michel   +30 more
openaire   +3 more sources

Acute ischemic stroke in adolescents

Neurology, 2020
Adolescence represents a transition period between childhood and adulthood, and only limited information exists about stroke characteristics in this population. Our aim was to describe the clinical and neuroradiologic features, etiologies, initial management, and outcome of ischemic stroke in adolescents.This retrospective cohort study evaluated all ...
Thomas Rambaud, Nicolas Legris, Yannick Bejot, Céline Bellesme, Bertrand Lapergue, Eric Jouvent, Fernando Pico, Didier Smadja, Mathieu Zuber, Sophie Crozier, Catherine Lamy, Laurent Spelle, Philippe Tuppin, Manoelle Kossorotoff, Christian Denier   +14 more
openaire   +2 more sources

Acute ischemic stroke therapy

Expert Review of Cardiovascular Therapy, 2010
Data from the European Cooperative Acute Stroke Study (ECASS) III trial demonstrated that tissue plasminogen activator given up to 4.5 h after stroke onset improves outcome and treatment guidelines support its use during this time window. Intra-arterial therapy with tissue plasminogen activator or devices is commonly used at large tertiary centers up ...
Henninger, Nils, Kumar, Rajat, Fisher, Marc   +2 more
openaire   +3 more sources

Acute Ischemic Stroke and Infections

Journal of Stroke and Cerebrovascular Diseases, 2011
We present an overview of multiple infections in relation to acute ischemic stroke and the therapeutic options available. Conditions that are a direct cause of stroke (infectious endocarditis, meningoencephalitides, and human immunodeficiency virus infection), the pathophysiologic mechanism responsible for stroke, and treatment dilemmas are presented ...
Catalina C, Ionita, Adnan H, Siddiqui, Elad I, Levy, L Nelson, Hopkins, Kenneth V, Snyder, Kevin J, Gibbons   +5 more
openaire   +2 more sources

Alteplase for acute ischemic stroke

Expert Review of Cardiovascular Therapy, 2006
Alteplase, an intravenously administered form of recombinant tissue plasminogen activator (rt-PA), remains the only US FDA-approved thrombolytic treatment for acute ischemic stroke within 3 h of symptom onset. Patients treated with intravenous rt-PA are at least 30% more likely to have minimal or no disability at 3 months compared with placebo. Despite
Nicole R, Gonzales, James C, Grotta
openaire   +2 more sources

Management of Acute Ischemic Stroke

Mayo Clinic Proceedings, 2004
The treatment of acute ischemic stroke has evolved from observation and the passage of time dictating outcome to an approach that emphasizes time from ictus, rapid response, and a dedicated treatment team. We review the treatment of acute ischemic stroke from the prehospital setting, to the emergency department, to the inpatient hospital setting.
Jimmy R, Fulgham, Timothy J, Ingall, Latha G, Stead, Harry J, Cloft, Eelco F M, Wijdicks, Kelly D, Flemming   +5 more
openaire   +2 more sources

Neuroprotection in acute ischemic stroke.

Acta neurologica Belgica, 2005
Neuroprotection of patients with acute ischemic stroke should start at the scene and continue in the ambulance with the assessment and treatment of the airway, breathing, circulation, body temperature, and blood glucose. The key goal in eligible patients should be fast vessel recanalization with intravenous recombinant tissue-type plasminogen activator
De Keyser, Jacques, Uyttenboogaart, M, Koch, M.w., Elting, J.w., Sulter, G., Vroomen, P.c., Luijckx, G.j.   +6 more
openaire   +2 more sources

Immunothrombosis in Acute Ischemic Stroke

Stroke
Ischemic stroke is one of the leading causes of disability and mortality worldwide. Thrombosis is the main pathological process of stroke and is therefore an important therapeutic target in stroke prevention. In recent years, with the development of endovascular treatment and therefore retrieving the thrombus for further investigation, evidence is ...
Yan Wang, Inge A. Mulder, Willeke F. Westendorp, Jonathan M. Coutinho, Diederik van de Beek   +4 more
openaire   +2 more sources